Fellowship · Plantation, FL
Sponsored by HCA Florida Healthcare
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
The Lancet. Haematology · 2024 · 85 citations · Harshad Amin
High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections.
Discoveries (Craiova, Romania) · 2021 · 106 citations · Harshad Amin
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
British journal of haematology · 2025 · 7 citations · Harshad Amin
Do Admitted COVID-19-Positive Patients on Anticoagulation Therapy Have a Reduced Hospital Stay and Disease Severity?
Cureus · 2022 · 2 citations · Harshad Amin
Hypercoagulopathy in Overweight and Obese COVID-19 Patients: a Single-Center Case Series.
Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2022 · 1 citations · Harshad Amin
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
The New England journal of medicine · 2026 · 2 citations · Harshad Amin
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Future oncology (London, England) · 2025 · 1 citations · Harshad Amin